Premier Alternatives

SpyGlass Pharma (NAS: SGP)

Surgical Devices · Aliso Viejo, CA · Founded 2019 · Publicly Held

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug… SpyGlass Pharma (NAS: SGP) is based in Aliso Viejo, CA and was founded in 2019. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $511 million (Feb 2026). It has raised $349 million across 2 recorded rounds; the latest was a $75 million Series D in Jun 2025.

Last price · $/share
—
Implied valuation
$510.6M
Total raised
$348.5M
Last round
Later Stage VC (Series D)
Jun 2025

SpyGlass Pharma (NAS: SGP) key facts

  • SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug…
  • SpyGlass Pharma (NAS: SGP)’s last known valuation is $510.6M (Feb 2026).
  • It has raised $348.5M across 2 recorded rounds; the latest was Later Stage VC (Series D) ($75.0M) in Jun 2025.
  • Notable investors include RA Capital Management, New Enterprise Associates, Sands Capital, Samsara BioCapital, Gilde Healthcare — 7 tracked in total.
  • Status: Publicly Held.
Free account
More of SpyGlass Pharma (NAS: SGP) with a free account
  • ·Watch SpyGlass Pharma (NAS: SGP): the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

SpyGlass Pharma (NAS: SGP) funding rounds

2 rounds
Jun 2025Later Stage VC (Series D)$75.0M▮
Jul 2023Later Stage VC (Series C)$90.0M▮
Full funding history →

SpyGlass Pharma (NAS: SGP) valuation

SpyGlass Pharma (NAS: SGP) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $511 million (Feb 2026). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.

How much has SpyGlass Pharma (NAS: SGP) raised?

SpyGlass Pharma (NAS: SGP) has raised $349 million in total; 2 of its rounds are on record. The largest on record was a $90 million Series C in Jul 2023; the most recent was a $75 million Series D in Jun 2025.

SpyGlass Pharma (NAS: SGP) investors

7 investors are on record for SpyGlass Pharma (NAS: SGP), including RA Capital Management, New Enterprise Associates, Sands Capital and Samsara BioCapital. The Series D in Jun 2025 drew 6 investors.

Comparable companies

Comparable surgical devices names by valuation on PrivateMarketView: Imperative Care ($1.6 billion), Eximis Surgical ($18.7 million) and FEMSelect ($17 million).

About SpyGlass Pharma (NAS: SGP)

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Industry
Surgical Devices
Sector
Healthcare
HQ
Aliso Viejo, CA, United States
Founded
2019
Employees
65
Ownership
Publicly Held

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$510.6M

SpyGlass Pharma (NAS: SGP)’s last known valuation, Feb 2026. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.